slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 90,421-90,450
Pages 3,685
Rows per page 30
Component
90,421-90,450 of 110,539
04
Includes a footnote regarding a 1-for-25 reverse stock split.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a pipeline chart format to show the development status of seven different programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
09
The slide uses a numbered list format to present strategic pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
19
Includes structural visualization of the epitope and two dose-response curves.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
31
The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
52
The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogee Therapeutics.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a series of icons to represent different scientific methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
55
The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
27
Excludes Credit Suisse. Includes specific commentary on Global Markets and Global Banking performance drivers.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & ApproachLoop · Maturity Curve1 hit
29
Includes a waterfall chart for pre-tax income and a summary table of revenues and expenses.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
30
The slide uses a waterfall bridge to explain the transition from a negative 2Q23 PBT to a projected break-even/positive state.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
32
UBS | Results Presentation Deck | 41 slidesUBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
37
The slide uses a waterfall chart to explain the variance between projected and actual negative goodwill for the Credit Suisse acquisition.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
38
The slide compares RWA (excl. operational risk) and LRD metrics across five asset classes: Equities, Macro, Loans, Securitized products, and Credit/HQLA.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
06
The slide uses a hub-and-spoke style diagram to show the flow of value between sellers, the platform, and fans.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a cloud icon to represent synchronization between desktop and mobile app interfaces.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a split-screen layout to contrast the loyalty program (left) and gamified engagement (right).Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
19
Uses a hub-and-spoke diagram to illustrate components of strategic flexibility.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations 1 hit
02
The slide features a baseball player image, likely a metaphor for 'hitting it out of the park' or performance.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit
05
The slide uses a process-like flow to connect GOV to Revenue to EBITDA, implying a conversion or waterfall relationship.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses a hub-and-spoke diagram to illustrate how various financial components contribute to 'Strategic Flexibility'.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations Beat · FinancialsLoop · Why Now1 hit